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AbstrACt
Objective Forced swimming test (FST) in rodents is a 
widely used behavioural test for screening antidepressants 
in preclinical research. Translational value of preclinical 
studies may be improved by appraisal of the quality of 
experimental design and risk of biases, which remains to 
be addressed for FST. The present protocol of a systematic 
review with meta-analysis aims to investigate the quality 
of preclinical studies employing FST to identify risks of 
bias in future publications. In addition, this protocol will 
help to determine the effect sizes (ES) for primary and 
secondary outcomes according to several aspects of the 
FST study design. 
search strategy, screening annotation, Data 
management Publications reporting studies testing 
different classes of antidepressants in FST will be collected 
from Medline, SCOPUS and Web of Science databases. 
A broad list of inclusion criteria will be applied excluding 
those studies whereby FST is used as a stressor or studies 
reporting data from co-treatments. For assessing the 
quality of the included publications, the quality checklist 
adapted by Collaborative Approach to Meta-Analysis and 
Review of Animal Data from Experimental Studies will 
be used. If the meta-analysis seems feasible, the ES and 
the 95% CI will be analysed. The heterogeneity between 
studies will be assessed by using the χ2statistic with 
n−1 degrees of freedom. Subgroup meta-analysis (meta-
regression, and if necessary, stratified regression) will be 
performed when possible according to characteristics of 
study design and study quality to assess their impact on 
efficacy of the treatments. In addition, funnel plotting, Egger 
regression, and ‘trim and fill’ will be used to assess the 
risk of publication bias. Results of this protocol will help to 
create rational methodological guidelines for application 
of FST in rodents and improve the quality and translational 
value of preclinical research on antidepressant discovery.
reporting A preliminary version of the present protocol 
has been preregistered with Systematic Review Facility 
(http:// syrf. org. uk/). A preprint version of the current 
protocol has been registered with Open Science 
Framework (https:// osf. io/ 9kxm4/). Results will be 
communicated in scientific meetings and peer-reviewed 
journals. We plan to conduct an anonymous and online 
survey within the scientific community to ask researchers 
about their perception of risk of bias and their experience 
with the publication of negative results.
IntrODuCtIOn
Major depression disorder (MDD) in humans 
is characterised by depressed mood and 
behavioural inhibition and often comes with 
social avoidance, generalised anxiety, eating 
disorders, sleeping and problems to cope with 
stress.1 Despite the difficulty in finding suit-
able models to mimic subjective, behavioural 
and neurobiological aspects of MDD, there 
are several animal models predictive of MDD 
treatment.2 3 Most of these animal models are 
based on behavioural responses of an animal 
to inescapable stress, providing a framework 
for several laboratory tests.4–7 Usually, ines-
capable stress induces behavioural inhibition 
(or immobility) that can be counteracted 
by antidepressant treatment.4–7 Therefore, 
behavioural tests in animals are employed as 
screening steps during the preclinical phase 
of antidepressant drug discovery. Forced 
swimming test (FST)4 in rats and mice is 
used in preclinical trials of antidepressants. 
FST is easy to run, inexpensive, sensitive and 
strengths and limitations of this study
 ► This protocol for systematic review will collect, with 
broad inclusion criteria, preclinical studies employ-
ing forced swimming test (FST).
 ► The present protocol has been preregistered with 
Open Science Framework.
 ► A preliminary version of the present protocol has 
been preregistered with Systematic Review Facility 
(Collaborative Approach to Meta-Analysis and 
Review of Animal Data from Experimental Studies).
 ► Results obtained with this systematic review and 
meta-analysis may help to create specific and ratio-
nal methodological guidelines for application of FST 
in rodents.
 ► High levels of heterogeneity between studies may 
limit the external validity of our results.
 ► The summary effect size may be overestimated by 
publication bias.
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relatively selective to known antidepressants (for review 
see Cryan et al2). One criticism that may apply to FST is 
the abundance of ‘positive results'8 that contrasts with 
the failure of antidepressant treatments in some clinical 
trials or therapeutics.9–11 There is an estimation that up 
to 50% of patients are resistant to the treatment with the 
antidepressants currently available.9 10 Many different 
reasons may account for the contrasting findings between 
preclinical and clinical data11 including individual vari-
ability, poor quality of the studies as well as publication 
bias. Publication bias in a preclinical field may inflate the 
estimated effect size (ES)12 13 leading to inflated expec-
tations of efficacy in clinical trials, which may explain 
partially the perceived contrast between fields.11 There-
fore, the aim of the present study is to evaluate the quality 
of published literature applying FST to detect effects of 
the treatment with antidepressants and the risk of bias in 
this research field.
Initially, a pilot study was performed to create a 
database and to standardise the methods for a system-
atic review.14 15 This pilot study started with a review in 
Medline and Embase retrieving more than 7000 publica-
tions by using expressions commonly found in the liter-
ature such as ‘forced swimming test’ OR ‘forced swim 
test’ OR ‘Porsolt test' OR ‘fst’. The combination of these 
with medical subject heading (MeSH) terms related to 
‘rodents'16 and ‘antidepressants'17 retrieved the publica-
tions more relevant for the present study. For screening 
purposes, a database containing bibliographical informa-
tion from retrieved publications was built. We applied 
inclusion and exclusion criteria in the screening steps. 
Forty references, randomly selected from the database, 
generated 20 references to the pilot study, that is, one 
reference in every two fitted the inclusion criteria. From 
the selected literature, parameters were taken to estimate: 
(1) Quality. (2) ES. (3) Heterogeneity. (4) Publication 
bias. Most of the studies included in the pilot study were 
published from 2007 onwards. The quality score scale, 
adapted from the Collaborative Approach to Meta-Anal-
ysis and Review of Animal Data from Experimental 
Studies (CAMARADES),18 19 revealed that 12 studies 
scored above the median score (mean=09, maximum=14, 
minimum=04); none of them scored the maximum (18) 
or the minimum (0) values of the scale. Interestingly, all 
studies reported ‘species or strain in the title, abstract 
or full text’ and none reported ‘sample size calculation’ 
or ‘concealment of treatment allocation’ indicating that 
year of publication may not influence the quality of the 
studies. The median scores for studies in rats and mice 
were equal to the overall median score. Most of the exper-
iments were performed in male animals. There were 34 
different experiments: 15 using tricyclic antidepressants, 
16 using selective serotonin reuptake inhibitors and 3 
using selective norepinephrine reuptake  inhibitors.
In the 34 experiments, there were 96 comparisons 
between experimental (439–470 animals) and control 
groups (276–287). In most of the mentioned experiments, 
a control group was compared with several different 
experimental groups generating significant and non-sig-
nificant results in a single experiment. The incidences of 
significant results for primary and secondary outcomes 
within the experiments were 88.2% and 84.6%, respec-
tively. Interestingly, the experiments also showing non-sig-
nificant results for primary outcomes were only 29.4% 
whereas most of the experiments (92.3%) also reported 
non-significant results for secondary outcomes. The high 
number of significant results as compared with the nega-
tive ones was also found in another study.8 In summary, 
these preliminary analyses indicated that quality scores 
will be independent of the publication date, the experi-
mental species as well as the type of antidepressant tested. 
The differences in sex, strains and ages may be a source 
of heterogeneity. In addition, it is expected that ‘random 
allocation to a treatment’, ‘concealment of treatment 
allocation’ and ‘sample size calculation’ will be neglected 
in this field of research. Moreover, these interim data 
suggest the existence of publication bias. Considering 
the sample used in the pilot study as the representative 
sample, the screening process may generate enough data 
(50% of publications in the database will fit inclusion 
criteria, ie, 2200 publications) for reliable estimation of 
the quality of the studies, ES, heterogeneity and publica-
tion bias in the field.
A preliminary version of this protocol was deposited 
in the Systematic Review Facility in February 2016.14 15 
The current version of the protocol was updated based on 
procedures available in CAMARADES following instruc-
tions by de Vries et al.20 A preprint version of the current 
text was preregistered with Open Science Framework ( 
osf. io/ 9kxm4). Meta-analysis will be performed after 
publication of the protocol in a journal with a peer-review 
system. The links containing preliminary versions of the 
protocol will be updated to acknowledge the existence of 
the final peer-reviewed version.
systematic review questions
 ► What is the quality level of these studies?
 ► Is there any relationship between quality scores 
and ES of outcomes reported in preclinical studies 
employing FST?
 ► Is there an influence of the study design or the ES in 
primary or secondary outcomes of these preclinical 
studies?
 ► Is there any risk of bias in preclinical studies employing 
FST for antidepressant research?
MeThods and analysis
systematic review in specialised literature
This protocol was formulated using the Systematic Review 
Center for Laboratory animal Experimentation format.20 
The search strategy is based on previously reported proto-
cols17 and consists of an update from our previous protocol 
registered in the CAMARADES platform.14 15 Medline, 
SCOPUS and Web of Science will be the databases selected. 
The search in Medline will be performed using the Pubmed 
platform (advanced search in http://www. ncbi. nlm. nih. 
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gov/ pubmed). The search in SCOPUS and Web of Science 
will be conducted accessing the ‘Periodicos Coordenação 
de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)’ 
platform (advanced search in http:// www- periodicos- 
capes- gov- br. ez46. periodicos. capes. gov. br/) at the Federal 
University of Santa Catarina. The selection of keywords 
was based on the different denominations of FST found 
in the literature (see tables 1–3). We decided to include in 
the review only the data from studies in rats and mice that 
are the most common laboratory species submitted to FST 
using the MeSH terms by Hooijmans et al.16 The list of anti-
depressants included in the research was by McCann et al.17 
The relevant period of publication started from 1977 when 
the first paper was published4 to December 2017.
Inclusion criteria
The following inclusion criteria will be applied to 
the systematic review outcome:
 ► Publication date: since 1977, the year the first paper 
was published, to present (December 2017).
 ► Language: any language.
 ► Animal species: rats and mice, regardless of age and 
sex.
Table 1 Keywords for search in the Medline database
‘rodentia’(MeSH Terms) OR mice(Tiab) OR mus(Tiab) OR mouse(Tiab) OR murine(Tiab) OR woodmouse(tiab) OR 
rats(Tiab) OR rat(Tiab) OR murinae(Tiab) OR muridae(Tiab) OR cottonrat(tiab) OR cottonrats(tiab) OR rodentia(Tiab) OR 
rodent(Tiab) OR rodents(Tiab)
#1
(((ssri) OR (ssris) OR (selective serotonin reuptake inhibitor) OR (selective serotonin reuptake inhibitors) OR (selective 
serotonin re-uptake inhibitor) OR (selective serotonin re-uptake inhibitors) OR (selective serotonin-reuptake inhibitors) 
OR (selective serotonin-reuptake inhibitor) OR (fluoxetine) OR (citalopram) OR (escitalopram) OR (fluvoxamine) OR 
(paroxetine) OR (sertraline) OR (dapoxetine) OR (snri) OR (ssris) OR (serotonin and norepinephrine reuptake inhibitors) 
OR (serotonin and norepinephrine reuptake inhibitor) OR (serotonin and norepinephrine re-uptake inhibitors) OR 
(serotonin and norepinephrine re-uptake inhibitor) OR (serotonin-noradrenaline reuptake inhibitors) OR (serotonin 
and norepinephrine reuptake inhibitors) OR (serotonin and norepinephrine reuptake inhibitor) OR (serotonin and 
norepinephrine re-uptake inhibitors) OR (serotonin and norepinephrine re-uptake inhibitor) OR (serotonin-norepinephrine 
reuptake inhibitors) OR (duloxetine) OR (levomilnacipran) OR (sibutramine) OR (bicifadine) OR (venlafaxine) OR 
(desvenlafaxine) OR (milnacipran) OR (tramadol) OR (TCA) OR (tcas) OR (tricyclic antidepressant) OR (tricyclic 
antidepressants) OR (tricyclic anti-depressant) OR (tricyclic anti-depressants) OR (amitriptyline) OR (butriptyline) OR 
(clomipramine) OR (desipramine) OR (dosulepin) OR (doxepin) OR (imipramine) OR (iprindole) OR (lofepramine) OR 
(melitracene) OR (nortriptyline) OR (opipramol) OR (protriptyline) OR (trimipramine) OR (sari) OR (saris) OR (serotonin 
antagonist and reuptake inhibitor) OR (serotonin antagonist and reuptake inhibitors) OR (serotonin antagonist and re-
uptake inhibitor) OR (serotonin antagonist and reuptake inhibitors) OR (etoperidone) OR (lorpiprazole) OR (mepiprazole) 
OR (lubazodone) OR (nefazodone) OR (trazodone) OR (NRI) OR (nris) OR (norepinephrine reuptake inhibitor) OR 
(norepinephrine reuptake inhibitors) OR (norepinephrine re-uptake inhibitor) OR (norepinephrine re-uptake inhibitors) 
OR (norepinephrine reuptake inhibitor) OR (norepinephrine reuptake inhibitors) OR (norepinephrine re-uptake inhibitor) 
OR (norepinephrine re-uptake inhibitors) OR (atomoxetine) OR (reboxetine) OR (viloxazine) OR (ndri) OR (ndri) OR 
(norepinephrine dopamine reuptake inhibitor) OR (norepinephrine dopamine reuptake inhibitors) OR (norepinephrine 
dopamine reuptake inhibitor) OR (norepinephrine dopamine reuptake inhibitors) OR (norepinephrine-dopamine reuptake 
inhibitor) OR (norepinephrine-dopamine reuptake inhibitors) OR (norepinephrine dopamine reuptake inhibitor) OR 
(norepinephrine-dopamine reuptake inhibitors) OR (norepinephrine and dopamine reuptake inhibitor) OR (norepinephrine 
and dopamine reuptake inhibitors) OR (norepinephrine and dopamine re-uptake inhibitor) OR (norepinephrine and 
dopamine re-uptake inhibitors) OR (norepinephrine dopamine reuptake inhibitor) OR (norepinephrine dopamine reuptake 
inhibitors) OR (norepinephrine dopamine re-uptake inhibitor) OR (norepinephrine dopamine re-uptake inhibitors) OR 
(noradrenaline-dopamine reuptake inhibitor) OR (noradrenaline-dopamine reuptake inhibitors) OR (noradrenaline-
dopamine re-uptake inhibitor) OR (noradrenaline-dopamine reuptake inhibitors) OR (norepinephrine and dopamine 
reuptake inhibitor) OR (norepinephrine and dopamine reuptake inhibitors) OR (norepinephrine and dopamine re-
uptake inhibitor) OR (norepinephrine and dopamine re-uptake inhibitors) OR (bupropion) OR (dexmethylphenidate) OR 
(methylphenidate) OR (ndra) OR (nras) OR (norepinephrine dopamine releasing agent) OR (norepinephrine dopamine 
releasing agents) OR (norepinephrine-dopamine releasing agent) OR (norepinephrine-dopamine releasing agents) OR 
(norepinephrine and dopamine releasing agent) OR (norepinephrine and dopamine releasing agents) OR (norepinephrine 
dopamine releasing agent) OR (norepinephrine dopamine releasing agents) OR (noradrenaline-dopamine releasing agent) 
OR (noradrenaline-dopamine releasing agents) OR (norepinephrine and dopamine releasing agent) OR (norepinephrine 
and dopamine releasing agents) OR (amphetamine) OR (dextroamphetamine) OR (dextromethamphetamine) OR 
(lisdexamfetamine) OR (teca) OR (texas) OR (tetracyclic antidepressant) OR (tetracyclic antidepressants) OR (tetracyclic 
antidepressant) OR (tetracyclic anti-depressants) OR (amoxapine) OR (maprotiline) OR (mianserin) OR (mirtazapine) 
OR (maoi) OR (maois) OR (monoamine oxidase inhibitor) OR (monoamine oxidase inhibitors) OR (isocarboxazid) 
OR (moclobemide) OR (phenelzine) OR (pirlindole) OR (selegiline) OR (tranylcypromine) OR (antidepressant) OR 
(antidepressants) OR (antidepressant) OR (anti-depressants))))
#2
(forced swimming test OR forced swimming tests OR forced swimming test, fst OR fst OR forced swim OR porsolt test 
OR porsolt tests)
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 ► Type of publication: all types of publications containing 
studies describing the effect of all classes of clinically 
tested antidepressant drugs in FST, compared with 
control animals treated or not with vehicle will be 
included, regardless of randomisation. The antide-
pressants included in this review will be dose listed in 
the protocol by McCann et al.17 In future studies, we 
intend to include publications containing information 
about candidate substances (plant-derived compounds 
such as polyphenols and terpenoids, and ketamine).
 ► Studies with any route, dose and treatment schedule 
for drug administration are eligible.
exclusion criteria
The following exclusion criteria will be applied to the 
inclusion criteria application outcome:
 ► Experiments using FST in rats or mice, only as a 
stressor, without showing the data of the behavioural 
measures.
 ► Experiments reporting data of co-treatments. The 
publications containing these experiments will be kept 
if they also report experiments with single treatments.
search strategy
Publications returned from the searches will be exported 
to a single reference manager file. Duplicate references 
will be deleted. Two investigators will independently eval-
uate the titles and abstracts obtained to assess if they meet 
the broad inclusion criteria and compare their results. If 
there is any discrepancy in included titles, consensus will 
be reached through discussion with a third investigator.
Data extraction
Data on outcome measures (primary and secondary) and 
attributes of study quality (see items 3.6, 3.7 and 3.8) will 
be recorded. One investigator will carry out initial data 
extraction and a second investigator will then check all 
data entered. Primary outcome measures extracted will 
Table 2 Keywords for search in the SCOPUS database
(rodentia OR mice) OR mus) OR mouse) OR 
murine) OR woodlouse) OR rats) OR rat) OR 
murinae) OR muridae) OR cottonian) OR 
cottonrat) OR rodentia) OR rodent) OR rodents) #1
(ssri OR ‘selective serotonin-reuptake inhibitor’ 
OR fluoxetine OR citalopram OR escitalopram 
OR fluvoxamine OR paroxetine OR sertraline 
OR dapoxetine OR snri OR ‘serotonin and 
norepinephrine reuptake inhibitor’ OR duloxetine 
OR levomilnacipran OR sibutramine OR 
bicifadine OR venlafaxine OR desvenlafaxine 
OR milnacipran OR tramadol OR TCA OR 
‘tricyclic antidepressant’ OR amitriptyline OR 
butriptyline OR clomipramine OR desipramine 
OR dosulepine OR doxepin OR imipramine OR 
iprindole OR lofepramine OR melitracen OR 
nortriptyline OR opipramol OR protriptyline OR 
trimipramine OR sari OR ‘serotonin antagonist 
and reuptake inhibitor’ OR etoperidone OR 
lorpiprazole OR mepiprazol OR lurasodone 
OR nefazodone OR trazodone OR nris OR 
‘norepinephrine reuptake inhibitors’ OR 
atomoxetine OR reboxetine OR viloxazine OR 
ndri OR ‘norepinephrine dopamine reuptake 
inhibitor’ OR bupropion OR dexmethylphenidate 
OR methylphenidate OR ndma OR nras OR 
‘norepinephrine dopamine releasing agent’ 
OR amphetamine OR dextroamphetamine OR 
dextromethylamphetamine OR lisdexamfetamine 
OR teca OR texas OR ‘tetracyclic antidepressant’ 
OR amoxapine OR maprotiline OR mianserin OR 
mirtazapine OR maoi OR ‘monoamine oxidase 
inhibitor’ OR isocarboxazid OR moclobemide 
OR phenelzine OR pirlindol OR selegiline OR 
tranylcypromine OR antidepressant)
#2
(‘forced swimming test’ OR ‘forced swimming 
tests’ OR ‘forced swimming test’ OR fst OR fst 
OR ‘forced swim’ OR ‘porsolt test’ OR ‘porsolt 
tests’)
#3
Table 3 Keywords for search in the Web of Science 
database
(rodentia OR mice) OR mus) OR mouse) OR 
murine) OR woodlouse) OR rats) OR rat) OR 
murinae) OR muridae) OR cottonian) OR cottonrat) 
OR rodentia) OR rodent) OR rodents) #1
(ssri OR ‘selective serotonin-reuptake inhibitor’) 
OR fluoxetine) OR citalopram) OR escitalopram) 
OR fluvoxamine) OR paroxetine) OR sertraline) 
OR dapoxetine) OR snri) OR ‘serotonin and 
norepinephrine reuptake inhibitor’) OR duloxetine) 
OR levomilnacipran) OR sibutramine) OR 
bicifadine) OR venlafaxine) OR desvenlafaxine) 
OR milnacipran) OR tramadol) OR TCA) OR 
tricyclic antidepressant) OR amitriptyline) OR 
butriptyline) OR clomipramine) OR desipramine) 
OR dosulepine) OR doxepin) OR imipramine) OR 
iprindole) OR lofepramine) OR melitracen) OR 
nortriptyline) OR opipramol) OR protriptyline) OR 
trimipramine) OR sari) OR ‘serotonin antagonist 
and reuptake inhibitor’) OR etoperidone) OR 
lorpiprazole) OR mepiprazol) OR lurasodone) 
OR nefazodone) OR trazodone) OR nris) 
OR ‘norepinephrine reuptake inhibitors’) OR 
atomoxetine) OR reboxetine) OR viloxazine) OR 
ndri) OR ‘norepinephrine dopamine reuptake 
inhibitor’) OR bupropion) OR dexmethylphenidate) 
OR methylphenidate) OR ndma) OR nras) OR 
‘norepinephrine dopamine releasing agent’) 
OR amphetamine) OR dextroamphetamine) OR 
dextromethylamphetamine) OR lisdexamfetamine) 
OR teca) OR texas) OR ‘tetracyclic 
antidepressant’) OR amoxapine) OR maprotiline) 
OR mianserin) OR mirtazapine) OR maoi) OR 
‘monoamine oxidase inhibitor’) OR isocarboxazid) 
OR moclobemide) OR phenelzine) OR pirlindol) OR 
selegiline) OR tranylcypromine) OR antidepressant)
#2
(‘forced swimming test’ OR ‘forced swimming 
tests’ OR ‘forced swimming test’ OR fst OR fst OR 
‘forced swim’ OR ‘porsolt test’ OR ‘porsolt tests’)
#3
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be the parameters (total or mean duration, percentage 
or punctuation) of immobility. Secondary outcome meas-
ures will be the parameters of active behaviours (swim-
ming, climbing and headshakes) and index of locomo-
tion (in the open field, or rotarod or another test).
Design of study
Data on study design will be recorded, including: species, 
strain, age, weight and sex of animals used; number of 
experimental groups and number of animals per group; 
number of experiments and replications; housing condi-
tions (food and water regimens, light cycle, tempera-
ture, size of the cage, length of housing the laboratory 
conditions); experimental conditions (time, illumina-
tion, dimensions of the tank, temperature and volume of 
water); FST protocol (single or repeated sessions, eg, only 
test, or pretest followed by one or more tests, length of 
swimming sessions); antidepressant subtype, dose (mg/
kg) or regimen (single or multiple), mode of action of 
administered antidepressant; timing of drug administra-
tion related to the time point of the outcome measure-
ment (test session of FST); methods of outcome meas-
urement (manual or automatised); statistical methods 
for comparing groups and specific data from behavioural 
measures (mean, SD or SE of mean); reporting of data 
exclusion or inclusion for analysis.
Quality of study
A checklist with 10 items adapted from CAMARADES18 19 
will be used to assess the quality of experimental design. 
Additionally, a user-defined checklist will be used to 
assess the quality of the protocols of FST. The items in the 
user-defined checklist were chosen considering previous 
experience of the authors (eg, Lino-de-Oliveira et al and 
Mezadri et al,6 7 and other published literature, eg, Porsalt 
et al, Detke et al and Petit-Demouliere et al4 5 21). Infor-
mation in the user-defined checklist is relevant to repro-
ducibility of the study. Publications will receive a point 
for compliance of each item in the checklist from which 
group median scores will be calculated.
Ten items in the checklist adapted from CAMARADES 
are: (1) Peer-reviewed publication. (2) Reporting species/
strain of animals in the title or abstract and in the full text. 
(3) Statement of compliance with animal welfare regula-
tions. (4) Use of animals with behavioural phenotype. (5) 
Reporting blinded assessment of outcome. (6) Statement 
of possible conflicts of interest. (7) Reporting randomis-
ation of treatment allocation. (8) Reporting sample size 
calculation. (9) Reporting criteria for inclusion and/or 
exclusion of data. (9) Reporting concealment of treat-
ment allocation.
Ten items in the user-defined checklist are: (1) 
Reporting sex of animals in the title or abstract or in 
the full text. (2) Reporting age or weight or phase of 
development of animals in the title or abstract or in the 
full-text reporting. (3) Reporting efforts for improving 
animal welfare (eg, environmental enrichment) and 
reducing the number of animals. (4) Reporting control 
of temperature and light phase in the animal house. 
(5) Reporting dimensions of the tank used in FST. (6) 
Reporting the volume or the height of the water in the 
tank. (7) Reporting the temperature of water used in FST. 
(8) Reporting the use of clean water in FST. (9) Control 
for impaired locomotion of animals. (10) Reporting 
method of behavioural measurements.
Outcome extraction
The number of animals (N), the mean (M), SD or SE of 
the primary outcome (parameters of immobility) will be 
extracted for each treatment comparison. When available 
in the publications, N, M, SD or SE of secondary outcomes 
(ambulation in the open field test or active behaviours 
in FST) will be extracted. Ambulation in the open field 
test is used in many studies to discard influence of treat-
ments on the motor function of animals (eg,4 6) while 
active behaviours in FST such as swimming and climbing 
may indicate mechanism of action of antidepressants in 
rats.5 In cases where the full data required for meta-anal-
ysis are not available in the text or tables in the publica-
tions, digital ruler software will be used to measure data 
from graphs. If information is completely unavailable in 
the publication, it will be requested directly from authors. 
When required data are not obtainable, such studies will 
be excluded from the analysis.
Meta-analysis
Analytical choices were made from pilot studies 
published elsewhere.13–15 Normalised mean difference 
will be used to calculate ES. SE of ES will be calculated for 
each comparison. In addition, the 95% CI of the ES will 
be calculated. Data will be aggregated using a weighted 
average method in which greater weight is given to 
more precise studies. For anticipated heterogeneity 
between studies, the random-effects model of DerSimo-
nian and Laird will be used, which is more conservative 
than fixed-effect models, given the weighting towards 
individual comparisons depends on the variance within 
those comparisons and on overall heterogeneity. The 
heterogeneity between studies will be assessed by using 
the χ2 statistic with n−1 degrees of freedom. To allow 
for multiple comparisons, a significance level will be 
set using Bonferroni correction taking into account the 
number of comparisons. Publication bias will be looked 
for using funnel plotting, Egger regression and ‘trim 
and fill’. Subgroup meta-analysis (meta-regression, and if 
necessary, stratified regression) will be performed when 
possible according to characteristics of study design and 
study quality to assess their impact on efficacy, as the 
following subgroups: species, strain, age, comorbidities 
(present/absent), FST protocol; antidepressant subtype, 
dose (mg/kg), regimen (single or multiple) and time 
of administration (relative to the test), time of outcome 
assessment (relative to the test), scores of quality check-
list, especially the use of randomisation and blinded 
assessment of outcome.18 19 22
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COnClusIOn
Problems in reproducibility of preclinical studies are one 
of the major concerns in antidepressant research. Impor-
tantly, medical decisions are grounded on clinical trials 
and these are based on results reported in preclinical 
studies. Therefore, the existence of publication or confir-
mation risk of bias as well as low statistical power and 
method quality prevent from obtaining accurate evidence 
for developing therapeutic interventions. Hence, results 
obtained with the present protocol for conducting 
a systematic review with meta-analysis of preclinical studies 
using FST for testing antidepressant responses in rodents 
intends to improve the quality and statistical power of 
future studies and to contribute towards applying the 
3R (R eplacement,  R eduction and  R efinement) princi-
ples in preclinical research.
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